Research
At Draupnir, we are extending the potential of protein degradation to target extracellular and membrane-bound proteins in a pioneering approach using our novel and differentiated, proprietary technology platform which harnesses lysosome receptors, and has the potential to revolutionise the field of TPD.
Our SORtilin-based lysosome TArgeting Chimeras (SORTACs) is a modular platform that extends PROTAC-like, event-driven pharmacology to the extracellular space. By exploiting the endogenous progranulin-sortilin interaction, we establish a general design principle for redirecting aggregates soluble and membrane proteins to lysosomal degradation. SORTAC activity can be genetically encoded, introduced by single-step chemical conjugation to antibodies, or implemented as fully synthetic, small molecule degraders with physicochemical properties comparable to classical PROTACs.
We have demonstrated robust and selective degradation of a wide range of clinically relevant targets, including cytokines, membrane proteins, and protein aggregates showing that SORTACs display hallmark degrader characteristics such as ternary complex formation and sustained, catalytic-like activity.
Sortilin is expressed in all disease-relevant tissues, providing broad applicability of Draupnir’s platform potential across multiple therapeutic areas.